A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples